Effectiveness of Different Remineralizing Strategies on the Management of Early Carious Lesions in Primary Teeth

January 27, 2025 updated by: Sarah Khairy, Alexandria University

Effectiveness of Different Remineralizing Strategies on the Management of Early Carious Lesions in Primary Teeth (Randomized Controlled Clinical Trial)

the primary aim of the study is remineralization of early carious lesions in primary teeth using different remineralizing agents of different remineralizing strategies when applied in an intensive mode. The secondary aim of the study is to compare their antibacterial effect against streptococcus mutans and their effect on reducing the size of the lesions.

Study Overview

Detailed Description

The primary aim of the study is to compare the effect of curodont repair fluoride plus (self-assembling peptide p11-4 with 0.5% sodium fluoride) with MI varnish (casein phosphopeptide amorphous calcium phosphate fluoride) and Colgate fluoride varnish (5% sodium fluoride) in remineralization of early carious lesions in primary anterior teeth. The study sample is consisted of 66 patients aged 3-6 years old with at least 2 white spot lesions in their primary anterior teeth who are assigned into control group (n=22): colgate fluoride varnish, test group 1(n=22): MI varnish and test group 2 (n=22) :curodont repair fluoride plus. Each material is applied once every 2 weeks for 3 times (intensive mode of application). The secondary aim of the study is to determine the antibacterial effect of each material against streptococcus mutans is compared by obtaining a plaque sample at baseline then after application by 48 hours, 1 months and 3 months and culturing using disk diffusion method for determining the log count of streptococcus mutans at each time point. Another secondary aim is to determine the change in lesion size at baseline and after 6 months and 12 months using standardized photographs with a digital camera.

Study Type

Interventional

Enrollment (Actual)

66

Phase

  • Early Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Professor
      • Alexandria, Professor, Egypt
        • Karin Dowidar

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  1. healthy children
  2. age range 3-6
  3. at least 2 early carious lesions

Exclusion Criteria:

  1. Children presenting with special health care needs or undergoing medical treatment for chronic or acute diseases.
  2. Application of fluoride varnish less than 3 months prior to study treatment.
  3. Any metabolic disorders affecting bone turnover.
  4. Concurrent participation in another clinical trial.
  5. Patients receiving any antibiotic within 1 month prior to plaque sample collection

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: curodont repair fluoride plus
self-assembling peptide (p11-4) with 0.05% sodium fluoride
biomimetic remineralizing agent
Other Names:
  • SAP P11-4
Experimental: CPP-ACPF varnish
casein phoshphopeptide amorphous calcium phosphate fluoride (CPP-ACPF )
remineralizing agents that acts as a fluoride booster
Other Names:
  • CPP-ACPF
Active Comparator: 5 % sodium fluoride varnish
5% sodium fluoride varnish
remineralizing agent that is used as a gold standard for remineralization
Other Names:
  • 5% NaF

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assessing the remineralization of early carious lesions in primary teeth
Time Frame: 3,6,9 and12 months
comparing the remineralization effect of different remineralizing agents both qualitatively by comparing the change in ICDAS -11 criteria and quantitatively by using laser fluorescence scores using kavo DIAGNOdent classic after intensive mode of application of the different remineralizing agents
3,6,9 and12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
comparing the change in esthetic appearance of early carious lesion before and after treatment
Time Frame: 12 months
comparing the change in lesion size using standardized photographs quantitatively by calculating pixel size of the lesion before treatment and after 6 and 12 months of intensive mode of application of the different remineralizing agents using ImageJ software program for image analysis. Assessing the esthetic appearance of the lesions will be done subjectively by using a visual analogue scale score from 1 to 7
12 months
comparing the antibacterial effect of different remineralizing agents against streptococcus mutans
Time Frame: 3 months
Supragingival plaque samples will be collected at baseline then after 48 hours, 1 months and 3 months of application of the materials in an intensive mode. log count of streptococcus mutans is determined using disk diffusion method using mitis salivaris agar plates
3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: karin dowidar, professor, Faculty of Dentistry, Alexandria University, Egypt

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 15, 2023

Primary Completion (Actual)

October 15, 2024

Study Completion (Actual)

October 15, 2024

Study Registration Dates

First Submitted

August 9, 2024

First Submitted That Met QC Criteria

August 20, 2024

First Posted (Actual)

August 22, 2024

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

January 27, 2025

Last Verified

January 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

only the results of the primary and secondary outcomes of the study will be published after study completion

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on White Spot Lesion

Clinical Trials on self assmbling peptide p11-4 combined with 0.05% fluoride

Subscribe